Oxford University Hospital deploys blood analyser as part of COVID screening mobihealthnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mobihealthnews.com Daily Mail and Mail on Sunday newspapers.
Israeli company Sight Diagnostic’s Sight OLO blood diagnostics device. Photo: Sight Diagnostics via Facebook.
CTech – Sight Diagnostics, an Israeli company that delivers lab-grade Full Blood Count (FBC) results in just a few minutes, has deployed its Sight OLO solution at the John Radcliffe Hospital, part of Oxford University Hospitals NHS Foundation. The deployment means that patients who attend the emergency departments have access to quick FBC testing as part of a rapid AI triage system for Covid-19.
Sight OLO helps with faster predictions to be made by CURIAL AI, a screening test developed by Oxford University that leverages the routine vital signs of patients alongside FBC results to determine the likelihood of a patient having Covid-19. The CURIAL algorithm was developed by Oxford University and has proven to be effective in ruling out the possibility of Covid-19 within patients in the first hour, as opposed to the 12-28 hour timeframe offered by Polymerase Chain Reaction
Sight Diagnostics® Expands to the Gulf Region through a Distribution Partnership with Phoenix Capital
Sight Diagnostics, the company delivering lab-grade Complete Blood Count (CBC) results in minutes, announced a distribution partnership with Phoenix Capital to extend Sight’s footprint in the Middle East. Through the partnership, Sight will provide OLO analyzers – the company’s decentralized, lab-quality diagnostic technology – to medical centers across the Middle East to help providers make quick and informed treatment decisions.
Most outpatient clinics in the United Arab Emirates are currently operating mini-labs with legacy diagnostic technologies like flow cytometry, which require large, expensive machines that aren’t suited for point-of-care (POC) settings. As such, there is an increasing demand for modern POC diagnostics in the Middle East and Africa, with the market projected to reach $2.85 billion by 2024.